PODCAST | Politics, Policy & Law

U.K. biotech, Aduhelm docs & 2022 approval trends  

Policy reprieve for U.K. biotech in the works. Plus: Aduhelm document drop, bright spots in FDA’s 2022 approvals, and 2023 hot takes

January 4, 2023 1:32 AM UTC

The U.K. government is signaling that life sciences companies will be shielded from changes to an R&D tax relief policy that would otherwise leave small biotechs losing millions of pounds, Washington Editor Steve Usdin said on the latest BioCentury This Week podcast. Usdin and his BioCentury colleagues discuss the behind-the-scenes initiative by the U.K. BioIndustry Association to protect companies from being affected by serious unintended consequences of the policy changes as they continue to weather the bear market.

BioCentury’s editors also assess documents released by Congress that shed light on the rationale of Biogen Inc. (NASDAQ:BIIB) for how it priced Alzheimer’s drug Aduhelm aducanumab-avwa, trends in FDA’s 2022 approvals and what the editorial team is looking for in the year ahead.

BCIQ Company Profiles

Biogen Inc.